Skip to content

Glaukos GKOS Interest And Other Expense Net

Discontinued — last reported Q4 '24

Segments

By segment

See full
Development And Commercialization Of Ophthalmic Therapies-$749K-179%

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept gkos:InterestAndOtherExpenseNet.

The official record: Glaukos’s 10-K, filed February 25, 2025, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's interest and other expense net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's interest and other expense net?
Glaukos (GKOS) reported interest and other expense net of $1.57M in Q4 2024.
How has Glaukos's interest and other expense net changed year-over-year?
Glaukos's interest and other expense net increased by 1026.9% year-over-year, from $139.5K to $1.57M.
What is the long-term trend for Glaukos's interest and other expense net?
Over 3 years (2021 to 2024), Glaukos's interest and other expense net has grown at a 13.4% compound annual growth rate (CAGR), from $4.31M to $6.29M.